Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents

Since BNT162b2 was approved to prevent COVID-19 in children, we aim to compare the safety and immunogenicity of the BNT162b2 vaccine in liver-transplanted (LT) and healthy adolescents. LT and healthy adolescents received two doses of 30 µg of BNT162b2. All were evaluated for total COVID-19 antibodie...

Full description

Bibliographic Details
Main Authors: Palittiya Sintusek, Supranee Buranapraditkun, Siriporn Khunsri, Varattaya Saengchaisukhonkit, Preeyaporn Vichaiwattana, Donchida Srimuan, Thanunrat Thongmee, Yong Poovorawan
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Vaccines
Subjects:
liver transplant
BNT162b2
adolescents
immune response
vaccine
Online Access:https://www.mdpi.com/2076-393X/10/8/1324

Internet

https://www.mdpi.com/2076-393X/10/8/1324

Similar Items